This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Otsuka Holdings Co., Ltd.
Drug Names(s): RFS 2000, 9-NC, rubitecan
Description: Orathecin, an orally active camptothecin, is a topoisomerase I inhibitor.
In September 2011, SuperGen announced it will begin operating under the name Astex Pharmaceuticals.
Astex and Otsuka
In September 2013, Otsuka and Astex announced that their respective Boards of Directors unanimously approved a transaction under which Otsuka will acquire all of the outstanding shares of Astex for $8.50 per share in cash representing a 48% premium to the average closing stock price for the prior 30 day period. The purchase price represents a fully diluted equity value of approximately $886 million. The tender offer for all outstanding shares of common stock of Astex is scheduled to expire at 12:00 AM ET on October 10, 2013, unless extended or earlier terminated. In October 2013, Otsuka announced that it completed the acquisition of Astex.
Pink Sheet SuperGen Orathecin rolling NDA
Pink Sheet SuperGen withdraws Orathecin EU application
Additional information available to subscribers only: